Compare Amgen, Inc. (AMGN) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Mesoblast Limited — how do they compare? Amgen, Inc. trades at $356.4 (market cap $196.12B), while Mesoblast Limited trades at $16.25 (market cap $2.00B). The key difference: Amgen, Inc. is far larger — about 98.1× Mesoblast Limited's market cap, and Amgen, Inc. pays a 2.77% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| AMGN | MESO | |
|---|---|---|
Market Cap | $196.12B | $2.00B |
Sector | Health | Technology |
52-Week High | $388.16 | $20.96 |
52-Week Low | $271.18 | $10.96 |
Enterprise Value | $241.41B | $2.00B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
MESO trades at $15.44, up 4.11% today, with a bullish technical signal from moving averages but overbought RSI near 89. The company reported a net loss of $102.14 million in 2025 despite an 80.52% gross margin, while recent news highlights Ryoncil revenue growth and FDA progress for its heart failure treatment, signaling a transition to commercial operations.
The outlook is cautiously optimistic, driven by product commercialization and pipeline advancements, but high cash burn and negative margins pose significant risks. Analyst consensus leans buy (45% of ratings), yet the stock's elevated P/S ratio of 30.52 demands careful valuation assessment amid ongoing losses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
